These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 39107288)

  • 1. 53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer.
    Sun Y; Patterson-Fortin J; Han S; Li Z; Nowicka Z; Hirohashi Y; Kilgas S; Yi JK; Spektor A; Fendler W; Konstantinopoulos PA; Chowdhury D
    Nat Commun; 2024 Aug; 15(1):6676. PubMed ID: 39107288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
    Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
    Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
    Bruand M; Barras D; Mina M; Ghisoni E; Morotti M; Lanitis E; Fahr N; Desbuisson M; Grimm A; Zhang H; Chong C; Dagher J; Chee S; Tsianou T; Dorier J; Stevenson BJ; Iseli C; Ronet C; Bobisse S; Genolet R; Walton J; Bassani-Sternberg M; Kandalaft LE; Ren B; McNeish I; Swisher E; Harari A; Delorenzi M; Ciriello G; Irving M; Rusakiewicz S; Foukas PG; Martinon F; Dangaj Laniti D; Coukos G
    Cell Rep; 2021 Jul; 36(3):109412. PubMed ID: 34289354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    Becker JR; Cuella-Martin R; Barazas M; Liu R; Oliveira C; Oliver AW; Bilham K; Holt AB; Blackford AN; Heierhorst J; Jonkers J; Rottenberg S; Chapman JR
    Nat Commun; 2018 Dec; 9(1):5406. PubMed ID: 30559443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
    Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
    Chen J; Li P; Song L; Bai L; Huen MSY; Liu Y; Lu LY
    Cell Death Differ; 2020 Sep; 27(9):2552-2567. PubMed ID: 32139898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Polα-primase fill-in synthesis.
    Mirman Z; Sasi NK; King A; Chapman JR; de Lange T
    Nat Cell Biol; 2022 Jan; 24(1):51-61. PubMed ID: 35027730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53-binding protein 1-Tudor-interacting repair regulator complex participates in the DNA damage response.
    Zhang A; Peng B; Huang P; Chen J; Gong Z
    J Biol Chem; 2017 Apr; 292(16):6461-6467. PubMed ID: 28213517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling.
    Oh G; Wang A; Wang L; Li J; Werba G; Weissinger D; Zhao E; Dhara S; Hernandez RE; Ackermann A; Porcella S; Kalfakakou D; Dolgalev I; Kawaler E; Golan T; Welling TH; Sfeir A; Simeone DM
    J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 36976649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
    Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity.
    Lim J; Rodriguez R; Williams K; Silva J; Gutierrez AG; Tyler P; Baharom F; Sun T; Lin E; Martin S; Kayser BD; Johnston RJ; Mellman I; Delamarre L; West NR; Müller S; Qu Y; Heger K
    Cancer Immunol Res; 2024 Jun; 12(6):663-672. PubMed ID: 38489753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination.
    Callen E; Zong D; Wu W; Wong N; Stanlie A; Ishikawa M; Pavani R; Dumitrache LC; Byrum AK; Mendez-Dorantes C; Martinez P; Canela A; Maman Y; Day A; Kruhlak MJ; Blasco MA; Stark JM; Mosammaparast N; McKinnon PJ; Nussenzweig A
    Mol Cell; 2020 Jan; 77(1):26-38.e7. PubMed ID: 31653568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1.
    Zhang F; Gong Z
    J Zhejiang Univ Sci B; 2021 Jan; 22(1):38-46. PubMed ID: 33448186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
    Ding L; Kim HJ; Wang Q; Kearns M; Jiang T; Ohlson CE; Li BB; Xie S; Liu JF; Stover EH; Howitt BE; Bronson RT; Lazo S; Roberts TM; Freeman GJ; Konstantinopoulos PA; Matulonis UA; Zhao JJ
    Cell Rep; 2018 Dec; 25(11):2972-2980.e5. PubMed ID: 30540933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
    Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition.
    Liu Z; Jiang H; Lee SY; Kong N; Chan YW
    Cell Rep; 2024 Jul; 43(7):114464. PubMed ID: 38985669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
    Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
    J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.